<DOC>
	<DOCNO>NCT01011699</DOCNO>
	<brief_summary>The comparison nicotinamide sevelamer aim demonstrate , chronic hemodialysed patient , non-inferiority nicotinamide term control phosphatemia . Secondary objective compare two treatment term efficiency biological parameter , vascular calcification bone mass loss clinical biological tolerance finally explore role metabolite nicotinamide .</brief_summary>
	<brief_title>Nicotinamide Versus Sevelamer Hydrochloride Phosphatemia Control Chronic Hemodialysed Patients</brief_title>
	<detailed_description>This multicenter randomize open study 2 treatment arm ( nicotinamide / Sevelamer ) . Laboratories dose biochemical parameter PTH , ignore treatment receive patient . The team measure bone density radiologist rheumatologist appreciate centrally calcification deformity vertebra , ignore treatment receive patient . Therefore 's Randomized Prospective Blinded Outcome Endpoint . Pre-recruitment period ( 3 6 month ) basic medication - Repletion vitamin D ( p 25 OHD 30 50 ng / ml ) ( require supplementation Dedrogyl weekly dialysis nurse ) - Bath dialysis 1.50 mmol / l calcium ( 1.75 mmol / l hemodiafiltration ) , 32 mmol bicarbonate 0.5 mmol / l magnesium - Support provide dietary protein intake 1.2 g / kg / assessment contribution Ca PO4 - Use CaCO3 take meal rich phosphorus ( morning , noon even ) without - In case hyperkalemia , Calcium Sorbisterit® preferably use instead KAYEXALATE® . This process expose worsen effect hyperphosphatemia increase calcium malabsorption therefore negative calcium balance renal failure . - Statin therapy , fibrate ezetimibe necessary , stable dose This treatment monitor follow parameter : - Biochemical weekly Predialytic ( midweek ) : creatinine , urea , PO4 , Ca , protein , Na , K , bicarbonate , glucose , uric acid - Additional monthly balance : PTH intact , Mg , albumin , CRP - Each 4 month update : lipid profile ( fast , always time , 25 OH D , complete blood count ( CBC ) , AST-ALT , total alkaline phosphatase , gamma-GT , PKC , glycated hemoglobin ( HbA1C ) ) Recruitment ( 180 patient ) : - Obtaining informed consent - Perform bone density DXA third radius ( cortical bone ) , radius ultradistal ( trabecular bone ) , femoral neck bone ( mixed ) , whole body lumbar spine profile radiography . - Lumbar dorsal radiography ( frontal profile ) research vertebral measurement aortic calcification Framingham score ) + pelvis radiography ( frontal ) 2 hand radiography ( frontal ) search vascular calcification , Looser 's streak subperiosteal resorption . - Freezing -80 ° C ( 4 tube 1 ml serum ) centralize analysis : PTH , 25 OHD , CTX , PAO . All sample send laboratory analysis Biochemistry University Hospital Amiens end study . For , 10 ml blood collect dry tube centrifuge 15 minute , 4000-5000 rpm room temperature within 30 minute collection . Then , aliquot 1ml 4 polypropylene tube careful take fibrin . - Freezing -80 ° C tube 2.5 ml plasma assay later metabolite nicotinamide . These sample achieve patient accept mark second part consent . The tube store biological resource center , CHU Amiens research indefinite period . The nicotinamide metabolite measure study annex Met2PY ( N-methyl-2-pyridone-5-carboxamide ) , Met4PY ( N-methyl-4-pyridone-3-carboxamide ) NAD ( nicotinamide adenine dinucleotide ) . 6 ml EDTA whole blood collect , centrifuge 15 minute , 4000-5000 rpm room temperature within 30 minute collection . Then , 2.5 ml aliquot 1 polypropylene tube . - Then heparinized blood sample 2.5 ml frozen -80 °C determination nicotinamide . All sample send analysis CERBA end study . Randomization do minimization technic stratification factor : center , duration dialysis take lipid lower therapy . Randomization perform remotely via website . Follow-up one year : - Period titration nicotinamide sevelamer control serum phosphorus 4 week , stable dos CaCO3 - Increased nicotinamide 500 mg 4 tablet : 0-1-0 , 0-1-1 , 1-1-1 , 1-2-1 - Increased sevelamer 800 mg 12 tablet : 0-2-2 ; 2-4-4 ; 4-4-4 ; 2-5-5 - Maintenance period 5 month assessment maintenance dos Renagel ( sevelamer ) Nicobion ( nicotinamide ) last 3 month . - After 6 month : - Freezing -80 ° C , 4 tube 1 ml serum centralized review PTH , 25 OHD , CTX , PAO ( mention ) . - Freezing -80 ° C tube 2.5 ml plasma assay later metabolite nicotinamide ( mention ) . - Freezing -80 ° C heparinized blood sample 2.5 ml determination nicotinamide ( mention ) . - Second randomization via website , patient intact PTH &gt; 300 pg / ml 6 month Nicobion ® Renagel ® . Randomization 75-150 pg / ml 150-300 mg / ml make minimization technic stratification factor : center type Hypophosphatemia PTH reduce introduce cinacalcet ® increment 30 mg every 3 week 180 mg / day ( give meal 24 hour next dialysis ) . Increase Cinacalcet ® stop PTH &lt; 250 pg / ml arm 150-300pg/ml &lt; 125 per arm 75-150 pg / ml . Once correct calcemia &lt; 2.25 mmol / l , dose CaCO3 increase ; maximum tolerable CaCO3 tract map prevent hypocalcemia ( &lt; 2.10 mmol / l ) , calcium bath increase 1.75 mmol / l CaCO3 decrease , necessary adjustment nicotinamide / Sevelamer maintain PO4 1.30 1.60 mmol / l. - During first 6 month administration sevelamer , weekly , monthly quarterly report do . Regarding PTH assay perform , every 3 week titration cinacalcet . - A lumbar dorsal radiography ( frontal profile ) , pelvis radiography ( face ) 2 hand radiography ( front ) conduct end follow-up period . - Bone densitometry perform end study ( camera - site ) . - Case report form : tolerance , serious adverse event , compliance , cardiovascular event ( myocardial infarction , PAO , stroke , arteritis , vascular intervention ) , deaths fracture follow-up study . - Freezing -80 ° C 4 tube 1 ml serum centralized review PTH , 25 OHD , CTX , PAO end study ( mention ) . - Freezing -80 ° C tube 2.5 ml plasma assay later metabolite nicotinamide end study ( mention ) . - Freezing -80 ° C heparinized blood sample 2.5 ml determination nicotinamide end study ( mention ) . Analytical Methodology</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Women men 18 year Chronic hemodialysis ( since 3 month ) Hyperphosphatemia control CaCO3 PO4 &gt; 1,60 mmol/l , PCa &lt; 2,37 mmol/l patient able understand sign inform consent form PTH &lt; 60 ou &gt; 800 pg/ml ( PTX ) Aluminium intoxication ( aluminium level blood &gt; 0,5 µmol/l ) Score aortic calcification ≥ 20 ( max 24 ) Characterized intolerance Renagel and/or Nicobion Pregnant woman Autoimmune disease Patient know bad drug compliance Blood test abnormality ( thrombopenia &lt; 150 000 , serum albumin &lt; 30g ) Hepatic test abnormality Transplant probably within 6 month Patient need transplantation within 6 month Patients receive chemotherapy Patients loss dry weight 3 kg 3 month 6 kg 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>nicotinamide</keyword>
	<keyword>sevelamer hydrochloride</keyword>
	<keyword>phosphatemia</keyword>
	<keyword>cinacalcet</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>vascular calcification</keyword>
	<keyword>bone mass loss</keyword>
</DOC>